The effect of latanoprost on accommodation in young patients with ocular hypertension

Journal of Glaucoma

Volumn 12, Issue 1, 2003, Pages 54-56

  Kurtz, Shimon ^a   Leibovitch, Igal ^a,b   Shemesh, Gabi ^a   Rothkoff, Levi ^a   Loewenstein, Anat ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Accomodation; Latanoprost; Ocular hypertension; Refraction

Indexed keywords

LATANOPROST;

ACCOMMODATION; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG INSTILLATION; EYE REFRACTION; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; PRIORITY JOURNAL; SHORT COURSE THERAPY; TREATMENT OUTCOME; TREATMENT PLANNING;

ACCOMMODATION, OCULAR; ADULT; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; INTRAOCULAR PRESSURE; MALE; OCULAR HYPERTENSION; PROSTAGLANDINS F, SYNTHETIC; REFRACTION, OCULAR;

EID: 0037329019     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/00061198-200302000-00011     Document Type: Article

References (16)

1. Kjellgren D, Douglas G, Mikelberg FS, et al. The short time effect of latanoprost on the intraocular pressure in normal pressure glaucoma. Acta Ophthalmol. Scan 1995;73:233-236.
2. Alm A, Stjernschantz J. Effect on intraocular pressure and side effect of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995;102:1743-1752.
3. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open angle glaucoma and ocular hypertension. The Latanoprost Study Group Study Group. Ophthalmology. 1996;103:126-137.
4. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology. 1996;103:138-147.
5. Camras CB, Alm A, Watson P, et al. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology. 1996;103:1916-1924.
6. Mishima HK, Masuda K, Kitazawa Y, et al. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol. 1996;114:929-932.
7. Ziai N, Dolan JW, Kacere RD, et al. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993;111:1351-1358.
8. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297-1304.
9. Lindsey JD, To HD, Weinreb RN. Induction of c-Fos by prostaglandin F2a in human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1994;35:242-250.
10. Weinreb RN, Kashiwagi K, Kashiwagi F, et al. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1997;38:2214-2223.
11. Lindsey JD, Kashiwagi K, Kashiwagi F, et al. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci 1997;38:2214-2223.
12. 2a treatment reduces collagen types I, III and IV in the monkey uveoscleral outflow pathways. Arch Ophthalmol. 1999;117:794-801.
13. Mishima HK, Shoge K, Takamatsu M, et al. Ultrasound biomicroscopic study of ciliary body thickness after topical application of pharmacologic agents. Am J Ophthalmol. 1996;121:319-321.
14. Lo Presti L, Morgese A, Ravot M, et al. Ultrabiomicroscopic study of the effects of brimonidine, apraclonidine, latanoprost and ibopamine on the chamber angle and ciliary body. Acta Ophthalmol Scand Suppl. 1998;227:32-34.
15. Poyer JF, Millar C, Kaufman PL. Prostaglandin F2 alpha effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol Vis Sci. 1995;36:2461-2465.
16. Troiano P, Oldani A, Gozzini C, et al. Latanoprost 0.005%: evaluation of its effect on accommodative capacity. Acta Ophthalmol Scand Suppl. 2000;78:52-54.